Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)

Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that it has reached a global settlement with AbbVie to resolve all ... Biopharmaceuticals, Generics, Litigation, Licensing Amgen, AbbVie, AMGEVITA, AMJEVITA, Humira, adalimumab, biosimilar
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news